Xencor ( XNCR ) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +47.44% and +116.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Xencor ( XNCR ) Q2 Revenue Jumps 82%
Xencor ( NASDAQ:XNCR ) , a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company's GAAP revenue of $43.6 million exceeded analyst estimates by $21.0 million and Revenue ( GAAP ) increased ...
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® ( tafasitamab ) for Follicular Lymphoma in Brazil
MONTREAL, July 31, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian ...
Aurinia Pharmaceuticals ( AUPH ) Q2 Earnings Miss Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development - Inovio Pharmaceuticals ( NASDAQ:INO )
LONDON and PHILADELPHIA, July 01, 2025 ( GLOBE NEWSWIRE ) -- Avacta Group plc AVCT, a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer ( CMO ) and Yulii Bogatyrenko as an advisor in ...
Xencor ( XNCR ) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -4.76% and 48.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Xencor ( XNCR ) Report Negative Q1 Earnings? What You Should Know
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor ( XNCR ) Upgraded to Buy: Here's Why
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Knight Therapeutics Announces Launch of Minjuvi® ( tafasitamab ) in Mexico - Incyte ( NASDAQ:INCY )
MONTREAL, March 26, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., GUD ( "Knight" ) , a pan-American ( ex-US ) specialty pharmaceutical company, announced today the launch of Minjuvi® ( tafasitamab ) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V.
Knight Therapeutics Announces Launch of Minjuvi® ( tafasitamab ) in Mexico
MONTREAL, March 26, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) , a pan-American ( ex-US ) specialty pharmaceutical company, announced today the launch of Minjuvi® ( tafasitamab ) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V.
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
Xencor ( XNCR ) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 25.30% and 293.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals ( BCRX ) Reports Q4 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -116.67% and 0.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx ( ARDX ) Meets Q4 Earnings Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of 0% and 4.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals ( ENTA ) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor ( XNCR ) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -21.69% in 4 Weeks, Here's Why Xencor ( XNCR ) Looks Ripe for a Turnaround
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor ( XNCR )
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Xencor ( XNCR ) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Xencor ( XNCR ) Upgraded to Strong Buy: Here's What You Should Know
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Xencor ( XNCR ) Rating Upgrade to Buy
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors
GUILFORD, Conn., Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- Invea Therapeutics, Inc. ( Invea ) , a leading biotechnology company developing an artificial intelligence ( AI ) , GenAI, and machine learning ( ML ) powered pipeline of transformational medicines for highly debilitating immune-mediated ...
Wall Street Analysts Think Xencor ( XNCR ) Could Surge 31.58%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Xencor ( XNCR ) Could Rally 53.53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xencor ( XNCR ) 's Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Xencor ( XNCR ) Reports Q3 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 27.55% and 38.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Does Xencor ( XNCR ) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 68.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Xencor ( XNCR ) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 68.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Jazz Pharmaceuticals ( JAZZ ) Earnings Expected to Grow: Should You Buy?
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor ( XNCR ) Expected to Beat Earnings Estimates: Should You Buy?
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 67.2% Upside in Xencor ( XNCR ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xencor Surges 10.5%: Is This an Indication of Further Gains? - Usana Health Sciences ( NYSE:USNA ) , Xencor ( NASDAQ:XNCR )
Xencor XNCR shares rallied 10.5% in the last trading session to close at $21.13. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.8% gain over the past four weeks.
Xencor ( XNCR ) Surges 10.5%: Is This an Indication of Further Gains?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
Xencor ( XNCR ) Reports Q2 Loss, Misses Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -25.88% and 0.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform
BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. ( "Biocytogen", HKEX: 02315 ) announced United States Patent and Trademark Office ( USPTO ) patent grant for independently developed RenLite® fully human common light chain mouse platform.
Akebia Therapeutics ( AKBA ) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor ( XNCR ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx ( ARDX ) Reports Q1 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
THOUSAND OAKS, Calif., May 2, 2024 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter 2024.
Xencor ( XNCR ) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Plamotamab Clinical Trials Global Bispecific Antibodies Market Drug Sales Report 2029
Delhi, March 17, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 Billion Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies
Xencor ( NASDAQ:XNCR ) Stock Rating Upgraded by StockNews.com
Xencor ( NASDAQ:XNCR ) Stock Rating Upgraded by ...
Xencor ( NASDAQ:XNCR ) Stock Rating Upgraded by StockNews.com
Xencor ( NASDAQ:XNCR - Get Free Report ) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a report issued on Saturday. Other equities analysts also recently issued research reports about the company.
Xencor ( NASDAQ:XNCR ) Downgraded by StockNews.com
Xencor ( NASDAQ:XNCR - Get Free Report ) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a research report issued on Friday.
Xencor ( NASDAQ:XNCR ) Downgraded by StockNews.com
Xencor ( NASDAQ:XNCR - Get Free Report ) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a report released on Friday. XNCR has been the subject of a number of other research reports.
Xencor ( XNCR ) Reports Q4 Loss, Misses Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -186.11% and 68.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
